WGS Stock Forecast & Price Target

GeneDx Holdings is supported by a powerful shift in reimbursement and clinical adoption, as Carelon’s 6/14/26 policy now recognizes WGS as medically necessary when criteria are met, validating exome/genome sequencing as a first-line diagnostic tool. Its outlook is further strengthened by a rising mix toward exomes/genomes, which reached 47% of volumes at Q4'25, alongside expectations for solid 30%+ WES/WGS volume growth in 2026, improving revenue capture, ASPs, and gross margins. The company is also investing aggressively to expand into pediatricians, NICU, prenatal, newborn screening, and new disease areas, while the $33M Fabric Genomics acquisition and FDA breakthrough designation enhance scale, interpretation capability, and long-term platform value.

GeneDx Holdings is facing a weaker fundamental setup after its Q1’26 revenue of $102 million missed expectations and adjusted net income came in at negative $8 million, while adjusted gross margin of 69% also fell short. Management further cut its 2026 revenue guide by $65 million to $475-490 million, trimmed core exome and genome growth expectations to 20%+ from 33-35%, and the miss stemmed from five separate buckets, raising concerns about forecasting quality and execution. Although volumes grew 34% year over year to 27.5k and cash stood at $172 million, softer ASPs near $3,300, reimbursement pressure, and delayed profitability reinforce a cautious outlook.